Clinical Study

A Phase 1B, Open Label Study Of Dalantercept Plus Sorafenib In Patients With Advanced Hepatocellular Carcinoma

Posted Date: May 15, 2019

  • Investigator: Olugbenga Olowokure
  • Specialties:
  • Type of Study: Drug

The purpose of this research study is to find out whether the study treatment can stop HCC from growing, or prevent it from growing as fast as it would without study treatment. This study will also evaluate the safety and tolerability of the study treatment in patients with HCC to determine the maxi

Criteria:

To Be Eligible For This Study, You Must Have Advanced Hepatocellular Carcinoma (Hcc) And You Require

Keywords:

Cancer, A041-05, Advanced Hepatocellu, Gi, Liver

For More Information:

Uc Cancer Institute
513-584-7698
kastla@ucmail.uc.edu


  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at ResearchStudies@UCHealth.com or (513) 245-3417.